{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T00:29:09.583508+00:00","company":{"ticker":"RKDA","cik":1469443,"company_name":"Arcadia Biosciences, Inc."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"auditor_change","fact_key":"6b47bdebc2bf94a9709d7ffc40319cd92c15033a","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-04-03T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Ramirez Jimenez International CPAs","disagreement_text":null,"effective_date":"2026-03-30","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Arcadia Biosciences, Inc. engaged Ramirez Jimenez International CPAs as its auditor.","evidence_excerpt":"the Audit Committee approved the engagement of Ramirez Jimenez International CPAs (“RJI”), effective immediately upon the dismissal of Deloitte, as the Company’s independent registered public accounting firm","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-142030","anchor_url":"https://secwatch.observer/filing/0001193125-26-142030#claim-6b47bdebc2bf94a9709d7ffc40319cd92c15033a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526142030/0001193125-26-142030-index.htm"},{"fact_type":"auditor_change","fact_key":"e24fb4024a4c3a3fee334291d6d33b539907259c","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-04-03T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Deloitte & Touche LLP","disagreement_text":null,"effective_date":"2026-03-30","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Ramirez Jimenez International CPAs"},"claim":"Arcadia Biosciences, Inc. dismissed Deloitte & Touche LLP as its auditor.","evidence_excerpt":"dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-142030","anchor_url":"https://secwatch.observer/filing/0001193125-26-142030#claim-e24fb4024a4c3a3fee334291d6d33b539907259c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526142030/0001193125-26-142030-index.htm"},{"fact_type":"earnings_release","fact_key":"c49afc7f389992925378457d12d8963428b98713","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-03-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2025","report_date":"2026-03-26","result_type":"reported_results","revenue_text":null},"claim":"Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.","evidence_excerpt":"On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-126220","anchor_url":"https://secwatch.observer/filing/0001193125-26-126220#claim-c49afc7f389992925378457d12d8963428b98713","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/0001193125-26-126220-index.htm"},{"fact_type":"material_agreement","fact_key":"91140180398ca6ab67adb7cb44c59b1071b241b2","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-01-14T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Inducement Letters","agreement_type":"equity_purchase","counterparty":"Participating Holders","effective_date":"2026-01-09","item_codes_triggered":["1.01"],"value_text":"Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options"},"claim":"Arcadia Biosciences, Inc. entered into Inducement Letters with Participating Holders valued at Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options (effective 2026-01-09).","evidence_excerpt":"On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock (\"Common Stock\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-012028","anchor_url":"https://secwatch.observer/filing/0001193125-26-012028#claim-91140180398ca6ab67adb7cb44c59b1071b241b2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/0001193125-26-012028-index.htm"},{"fact_type":"material_agreement","fact_key":"343e0e93365b9fdef53c7870b567c0498d47dbcb","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2025-12-29T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Securities Exchange Agreement","agreement_type":"merger","counterparty":"Roosevelt Resources, LP","effective_date":"2025-12-24","item_codes_triggered":["1.02"],"value_text":null},"claim":"Arcadia Biosciences, Inc. terminated Securities Exchange Agreement with Roosevelt Resources, LP (effective 2025-12-24).","evidence_excerpt":"On December 24, 2025, the Company received a notice from Roosevelt indicating that it was terminating the Exchange Agreement with immediate effect pursuant to the Termination Provisions","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-335410","anchor_url":"https://secwatch.observer/filing/0001193125-25-335410#claim-343e0e93365b9fdef53c7870b567c0498d47dbcb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312525335410/0001193125-25-335410-index.htm"},{"fact_type":"executive_change","fact_key":"d5f8e61ced","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-08-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-01","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas J. Schaefer was appointed as Class I Director at Arcadia Biosciences, Inc..","evidence_excerpt":"On August 1, 2024, the board of directors (the “Board”) of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) appointed Thomas J. Schaefer, Arcadia’s current president and chief executive officer, to serve as a Class I director of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-092432","anchor_url":"https://secwatch.observer/filing/0000950170-24-092432#claim-d5f8e61ced","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024092432/0000950170-24-092432-index.htm"},{"fact_type":"executive_change","fact_key":"74d85afc85","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-07-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-05","interim":false,"role":"chief financial officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Mark Kawakami was appointed as chief financial officer at Arcadia Biosciences, Inc..","evidence_excerpt":"Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-082092","anchor_url":"https://secwatch.observer/filing/0000950170-24-082092#claim-74d85afc85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm"},{"fact_type":"executive_change","fact_key":"bff8e7b513","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-07-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-07-05","interim":false,"role":"president and chief executive officer","role_category":"ceo","successor_name":"Mark Kawakami","successor_named":true},"claim":"Thomas J. Schaefer was appointed as president and chief executive officer at Arcadia Biosciences, Inc..","evidence_excerpt":"Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-082092","anchor_url":"https://secwatch.observer/filing/0000950170-24-082092#claim-bff8e7b513","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm"},{"fact_type":"executive_change","fact_key":"5a13e339e9","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-07-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-02","interim":false,"role":"president, chief executive officer and director","role_category":"ceo","successor_name":"Thomas J. Schaefer","successor_named":true},"claim":"Stanley Jacot, Jr. resigned as president, chief executive officer and director at Arcadia Biosciences, Inc..","evidence_excerpt":"Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-082092","anchor_url":"https://secwatch.observer/filing/0000950170-24-082092#claim-5a13e339e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024082092/0000950170-24-082092-index.htm"},{"fact_type":"ma_transaction","fact_key":"2affdef0a9a28156e3a0e050106a512807fb15fa","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2024-05-13","consideration_text":"$4,000,000 in cash","counterparty":"Pioneer Hi-Bred International, Inc.","effective_date":"2024-05-13","item_codes_triggered":["2.01"]},"claim":"Arcadia Biosciences, Inc. completed a disposition involving Pioneer Hi-Bred International, Inc. for $4,000,000 in cash (closed 2024-05-13).","evidence_excerpt":"worked to introgress the resistant starch durum wheat trait into elite germplasm lines. As consideration for the sale and license of Purchased Assets, Pioneer paid to Arcadia $4,000,000 in cash, which consideration was determined based on negotiations between the parties. The Agreement includes a number customary provisions addressing matters such as closing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-061526","anchor_url":"https://secwatch.observer/filing/0000950170-24-061526#claim-2affdef0a9a28156e3a0e050106a512807fb15fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024061526/0000950170-24-061526-index.htm"},{"fact_type":"material_agreement","fact_key":"857ba4185a1a838273ac149eb0eb96a38a25cd93","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Pioneer Hi-Bred International, Inc.","effective_date":"2024-05-13","item_codes_triggered":["1.01"],"value_text":"$4,000,000 in cash"},"claim":"Arcadia Biosciences, Inc. entered into Asset Purchase Agreement with Pioneer Hi-Bred International, Inc. valued at $4,000,000 in cash (effective 2024-05-13).","evidence_excerpt":"On May 13, 2024, Arcadia Biosciences, Inc. (“Arcadia”) entered into an Asset Purchase Agreement (the “Agreement”) with Pioneer Hi-Bred International, Inc. (“Pioneer”), an indirect, wholly-owned subsidiary of Corteva, Inc., pursuant to which on May 13, 2024 Arcadia sold or licensed to Pioneer certain patent and related rights associated with Arcadia’s resistant starch durum wheat trait (“Purchased Assets”).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000950170-24-061526","anchor_url":"https://secwatch.observer/filing/0000950170-24-061526#claim-857ba4185a1a838273ac149eb0eb96a38a25cd93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024061526/0000950170-24-061526-index.htm"},{"fact_type":"earnings_release","fact_key":"c466a6040aecf6f4af7dd6e4493ca03509269043","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Arcadia Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-056928","anchor_url":"https://secwatch.observer/filing/0000950170-24-056928#claim-c466a6040aecf6f4af7dd6e4493ca03509269043","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024056928/0000950170-24-056928-index.htm"},{"fact_type":"earnings_release","fact_key":"4feb1ad27f0ae51f48ff21b61e113358c584fc5c","cik":1469443,"ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2023","report_date":"2024-03-28","result_type":"reported_results","revenue_text":null},"claim":"Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-038153","anchor_url":"https://secwatch.observer/filing/0000950170-24-038153#claim-4feb1ad27f0ae51f48ff21b61e113358c584fc5c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1469443/000095017024038153/0000950170-24-038153-index.htm"}]}